Table 2.

Associations between vitamin D pathway SNPs and prostate cancer risk (cases vs controls)

Polymorphism	Major/minor allele	25(OH)D-increasing allelea	n (cases/controls)			Effect of minor alleleb
			Major homozygote	Heterozygote	Minor homozygote	OR	(95 % CI)	p value
CYP2R1 rs10741657	G/A	A	349/637	485/887	204/351	1.00	(0.90, 1.13)	0.94
CYP2R1 rs2060793	G/A	A	349/637	485/887	204/351	1.00	(0.90, 1.13)	0.94
DHCR7 rs12785878	T/G	T	621/1177	372/601	45/97	1.07	(0.93, 1.23)	0.32
NADSYN1 rs3829251	G/T	A	790/1418	233/421	15/36	0.97	(0.82, 1.15)	0.75
Synthesis score c	High–low					1.03	(0.94, 1.12)	0.56
VDBP rs2282679	T/G	T	504/948	433/757	101/170	1.09	(0.96, 1.23)	0.17
VDBP rs4588	C/A	C	461/465	400/358	92/75	1.20	(1.01, 1.41)	0.04
VDBP rs7041	G/T	G	275/295	473/430	201/175	1.19	(1.02, 1.38)	0.03
VDBP rs1155563	T/C	T	513/955	421/741	104/179	1.04	(0.92, 1.18)	0.52
CYP24A1 rs6013897	T/A	T	665/1220	348/577	25/78	1.01	(0.87, 1.17)	0.92
CYP27B1 rs703842	A/G	A	456/866	466/814	116/195	1.06	(0.93, 1.19)	0.38
CYP27B1 rs10877012	G/T	G	405/413	408/377	111/91	1.02	(0.86, 1.20)	0.85
Metabolism score d	High–low					0.97	(0.85, 1.10)	0.6
VDR ApaI	A/C	A	259/251	489/419	202/220	0.94	(0.81, 1.10)	0.45
VDR BsmI	G/A	A	342/334	468/423	144/138	1.07	(0.91, 1.25)	0.41
VDR FokI	G/A	G	353/339	486/425	111/131	1.06	(0.90, 1.25)	0.51
VDR TaqI	T/C	C	345/339	465/433	144/130	1.06	(0.91, 1.25)	0.45
VDR Cdx2	G/A	G	599/560	296/298	56/40	1.03	(0.86, 1.24)	0.72

OR odds ratio, CI confidence interval

^aDetermined from ProtecT data (presented in Table 1)

^bCase versus control models are calculated using conditional logistic regression, stratum matched on 5 years age band and GP surgery. Models additionally included exact age and 10 principal components to account for confounding by population stratification

^cSynthesis score: rs10741657, rs12785878

^dMetabolism score: rs6013897, rs10877012